Drugs / Epirubucin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02533700 | Sep 2015 → May 2019 | ALK-negative anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma +2 | Shandong Provincial Hospital | Unknown | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epirubucin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02533700 ↗ |
| Route | Intravenous | “Epirubucin 70mg/m2,ivgtt D1” NCT02533700 ↗ |